Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Visit NurExone Biologic Inc.

NurExone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons.



Bullboard - Investor Discussion Forum NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

NurExone Biologic Inc. is a pharmaceutical company. The Company is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and proprietary sIRNA sequence as the active... see more

TSXV:NRX - Post Discussion

NurExone Biologic Inc. > Exosome Based Therapies
View:
Post by javaman12 on Jan 14, 2025 11:02pm

Exosome Based Therapies

NurExone chose to base its ultimate drug delivery platform on exosomes-nanosized extracellular vesicles-due to their natural ability to reach inflamed or damaged tissue. By loading exosomes with therapeutic compounds, nanodrugs are created having natural regenerative properties and therapeutic impact.

Type 2 Diabetes could become one such disease that NurExone exoxome based therapies may one day address! Inflamation occurs naturally throughout the human body and sometimes it tends to feed upon itself with very destructive consequences.


https://nurexone.com/


As type 2 diabetes starts to develop, the body becomes less sensitive to insulin and the resulting insulin resistance also leads to inflammation. A vicious cycle can result, with more inflammation causing more insulin resistance and vice versa. Blood sugar levels creep higher and higher, eventually resulting in type 2 diabetes.

Emotional stress can also increase levels of the chemicals of inflammation. It's unknown whether stress by itself can contribute to the development of diabetes, though.

Does inflammation cause diabetes? It's not as simple as that, however, researchers know for sure that inflammation is somehow involved in the development of type 2 diabetes.

https://www.webmd.com/diabetes/inflammation-and-diabetes

NurExone's therapies are going to make their shareholders very wealthy persons! It's just a matter of time!

Inflammation in the human body needs to be addressed in the most efficacious and cost effective manner! Exosomes are the bodies nutural means to heal itself quickly! 

                  NurExone has the process that batch produces plenty of them!

                                                         All the best! Java


                                                   
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.NRX



Investor Presentation

View the Presentation

Investment Opportunity

NurExone operates according to two business lines – Development of a first exosome-based therapy for acute Spinal Cord Injuries (SCI).

In parallel, the company is monetizing its proprietary ExoTherapy platform through licensing to the global biopharmaceutical industry to deliver therapies for other diseases and indications.

The company’s first product, ExoPTEN, for acute spinal cord injury, has been granted Orphan Drug Designation by the FDA.



The Watchlist

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Why NurExone??

The Ultimate Drug Delivery System

The Beginning of NurExone

Facebook

Contact Us

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com

Dr. Eva Reuter Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu